Acurx Pharmaceuticals, Inc.

NASDAQ: ACXP · Healthcare · Biotechnology

PublicHQ Staten Island, NY · RichmondCIK 0001736243Reports USD

#1 of 1,394 Healthcare companies by revenue

EA Score

——

FH 36DQ —GM —SS 23

v0.1 · 35/100 weight · pillars only

↑ balance-sheet leverage, filing timeliness · ↓ workforce scale, listing tenure

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$8.0M

Employees

Market cap

$2.5M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$8.0M-$8.0M2025

Operating income-$8.1M-$8.1M2025

Total assets$7.7M$7.7M2025

Liabilities$2.4M$2.4M2025

Equity$5.3M$5.3M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Acurx Pharmaceuticals, Inc. earned -$8.0M in FY2025 net income.

Peers · Healthcare

Bone Biologics Corporation45D VivoSim Labs, Inc.——Accustem Sciences Inc.——Artelo Biosciences, Inc.——

Neighbors

Richmond →

ES Bancshares, Inc.——Coffee Holding Co., Inc.$96.3M61C

Key facts

CEODavid Luci

SectorHealthcare

IndustryBiotechnology

HeadquartersStaten Island, NY

ExchangeNASDAQ: ACXP

Employees4

IPO date2021-06-25

Latest filings

10-Q2026-05-11 8-K2026-04-16 10-K2026-03-12 8-K2026-03-09 10-Q2025-11-12 8-K2025-09-22 8-K2025-09-19 10-Q2025-08-11

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.